Frontlight ResearchEarly access
CompletedPhase 2
IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])
Key facts
- Who runs it
- Transcend Therapeutics Inc.
- Where
- Ireland2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 20 people enrolled
- Started
- 13 Jun 2024
- Ended
- 12 Aug 2025
- Type of study
- Interventional
- Record updated
- 16 December 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Prior participation in trial number TT-TSND-201 (IMPACT-1)
Who cannot take part
- Any significant change in social or medial history which would preclude participation in this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the long-term efficacy of methylone in participants with PTSD.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A 52-Week, Open-Label Evaluation of the Long-term Efficacy and Safety of Single and Repeated Treatments with Methylone for the Treatment of PTSD IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])
- Record updated
- 16 December 2024